Survodutide
Also known as BI 456906
A weekly injection being tested for weight loss and fatty liver disease. It acts on both GLP-1 and glucagon.
Quick facts
- Status
- Investigational — not approved yet
- Evidence
- Investigational (phase 3 trials)
- Taken as
- Injection under the skin once a week (in trials)
- Common sizes
- 10 mg
- Category
- GLP-1/glucagon receptor agonist · weight & liver (investigational)
How it works
It lowers hunger like other GLP-1 drugs and also targets glucagon, which helps burn fat stored in the liver.
What people use it for
- Obesity (in clinical trials)
- Fatty liver disease, MASH (in clinical trials)
What the research shows
- Phase 3 trials in 2026 showed up to about 16% weight loss.
- Promising results for reducing liver fat.
- Not approved yet.
Side effects & risks
- Stomach side effects were common — many trial participants stopped because of them
- Products sold online are not the trial drug
Is it legal?
Investigational — not approved anywhere as of October 2026. Phase 3 SYNCHRONIZE trials reported positive weight-loss results in 2026. The FDA has given it Breakthrough Therapy designation for MASH with fibrosis.
Storage & safe handling
- Mix with bacteriostatic water: let it run slowly down the inside of the vial and swirl gently — never shake.
- Store the mixed vial in the fridge and follow the use-by period on the label.
- Wipe the vial top with alcohol and use a new sterile needle and syringe every time.
- Rotate injection sites so the same spot is not used again and again.
- Put used needles in a sharps container, not the household bin.
- Get medical help for redness that spreads, fever, swelling or trouble breathing.
Open in PepTimerTrack your protocol, calculate how much to draw and get reminders — free.Open in PepTimer
Sources: Boehringer Ingelheim SYNCHRONIZE-1 and -2 phase 3 results (2026).
Last updated 12 October 2026. Information — not medical advice. PepTimer does not replace a doctor. Many peptides are not approved medicines in the EU, UK or US. Talk to a qualified healthcare provider before starting, changing or stopping any treatment.
Last updated 12 October 2026. Information — not medical advice. PepTimer does not replace a doctor. Many peptides are not approved medicines in the EU, UK or US. Talk to a qualified healthcare provider before starting, changing or stopping any treatment.